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Novel anti-androgen receptor signaling agents 311. IntroductionProstate cancer (PCa) is the most frequently diagnosed
cancer and the second leading cause of death by cancer
in men in western countries [1]. The critical role of the
androgen receptor (AR) in the progression of this disease
has been described thoroughly [2], while its role in PCa
development is more controversial [3]. Thus, for more
than 60 years systemic hormonal therapy aimed at
decreasing secretion of testosterone by the testes has
been the mainstay of therapy for patients with meta-
static disease. However, despite an initial response,
metastatic disease eventually progresses in the majority
of cases upon systemic androgen depletion, a state
known as castration-resistant prostate cancer (CRPC)
which is characterized by significant morbidity and
mortality [4]. Notably, a minority of cases of metastatic
disease presents with initial resistance to systemic hor-
monal therapy; for these cases, clinicians need to
consider alternative therapeutic approaches, including
chemotherapy such as taxanes (Data reported at 2014
ASCO Annual Meeting, Abstract No.: LBA2) and carbo-
platin [5] or novel agents targeting oncogenic signaling,
such as cabozatinib [6].
The findings that AR is amplified [7] and its down-
stream signaling remains active under systemic androgen
deprivation [8] led to introduction of agents targeting
either androgen biosynthesis in the tumor microenviron-
ment, such as abiraterone acetate (AA), or AR signaling,
such as enzalutamide. It should be noted that, according
to recent studies, ARN-509, a new AR inhibitor, provides
stronger inhibitory effects than enzalutamide. Numerous
clinical trials confirmed the efficacy of these agents in
patients with CRPC [9e13], even those who had received
no previous chemotherapy [14], indicating that these
agents are the optimal therapeutic approach for this
state of disease. However, the progression-free survival
and overall survival advantages that these agents provide
in patients with CRPC are relatively poor and all of these
patients eventually develop resistance [15e17]. No
known therapeutic approach has been shown to be
effective for patients whose disease becomes resistant to
these novel anti-androgen agents, although cabazitaxel
has shown evidence of efficacy for PCa that is resistant to
AA [18]. This conclusion suggests that a greater under-
standing of the molecular mechanisms involved in the
development of resistance to novel anti-androgen agents
is critical for the development of new approaches that
will improve the quality of life and survival of patients
with CRPC.
The aim of this review was to briefly summarize the
current clinical trial literature with regard to novel anti-AR
signaling agents such as AA and enzalutamide, and to
discuss insights into the mechanisms of resistance that
emerged from these studies. We also present recent
experimental studies that address the mechanisms of
resistance to these treatments. Finally, novel and rational
therapeutic approaches, including combination therapy, for
patients with CRPC are also discussed.2. Novel anti-AR signaling agents
2.1. Novel inhibitors of androgen synthesis: AA
Numerous reports support the finding that androgen
biosynthesis in adrenal glands and the tumor microenvi-
ronment are strongly implicated in the development of
CRPC [19]. In particular, CYP17A1, a steroidogenic
enzyme implicated in the conversion of progestins to
adrenal androgens, increasing the subsequent production
of testosterone and dihydrotestosterone, is induced in
metastatic CRPC (mCRPC) compared to primary PCa [19].
These findings led to introduction of AA, which inhibits
CYP17A1, leading to significant decrease of testosterone
levels in the tumor microenvironment [20]. Phase III
clinical trials enrolling patients with mCRPC in pre- and
post-docetaxel settings demonstrated that AA plus pred-
nisone prolonged overall survival in the post-docetaxel
setting and radiologic progression-free survival in the
pre-docetaxel setting [11,12]. These findings were asso-
ciated with evidence of efficacy in decreasing serum an-
drogens [21]. On the basis of these results, AA was
approved for mCRPC in both pre- and post-docetaxel
settings during the last year.
In a recent observational study, Efstathiou et al. [20]
evaluated the effects of AA in 57 patients with mCRPC.
The authors demonstrated a 50% reduction of prostate-
specific antigen (PSA) level in 50% of patients and showed
that stronger pre-treatment nuclear AR and CYP17A1
cytoplasmic staining were associated with longer treatment
duration (>4 months), suggesting better clinical response.
These observations suggested that AA-mediated androgen
depletion in the tumor microenvironment may be more
effective in patients with evidence of active AR and upre-
gulated CYP17A1. Unfortunately, the clinical data also
suggested that almost all patients will eventually experi-
ence disease progression during AA treatment. According to
another study, notably, the TMPRSS: ERG fusion gene,
which is considered to be an AR target, is not predictive of
the outcome of AA therapy [22].
Interestingly, VCaP xenografts in which the disease
relapsed during AA therapy were found to have induced
CYP17A1, while human CRPCs treated with ketoconazole,
which also inhibits CYP17A1, showed higher levels of
CYP17A1 than untreated CRPC [16]. Moreover, Mostaghel
et al. [17] showed that AA decreased tumor androgens but
also induced CYP17A1 expression in LuCaP23CR and
LuCaP35CR human xenografts. These findings suggest that
PCa cells expressing CYP17A1 may develop particular de-
pendency on these enzymatic pathways, while the devel-
opment of resistance to AA may be related to upregulation
of CYP17A1. Moreover, CYP11A1 mediates progesterone
synthesis from cholesterol, leading to accumulation of this
metabolite during AA treatment, while a mutant form of AR
(T877A) expressed in LNCaP and LNCaP C4-2 PCa cells has
been found to respond to progesterone [23], further sug-
gesting that upregulation of androgen biosynthesis path-
ways in PCa cells is implicated in the development of
resistance to AA.
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treatment with AA may have an impact on the efficacy of
subsequent chemotherapy, particularly taxanes. With re-
gard to this question, taxanes have been shown to inhibit
AR transcriptional activity [24], mainly through inhibition of
microtubule-mediated nuclear translocation of AR. These
findings were further supported by the results of a recent
study that showed that AR splice variants are implicated in
the development of resistance to taxanes [25]. In a retro-
spective analysis of CRPC patients who were either treated
or not treated with AA prior to docetaxel, Schweizer et al.
[26] found that men treated with AA prior to docetaxel
therapy were more likely to progress on docetaxel
compared to those who did not receive prior AA. Similarly,
docetaxel was shown to decrease PSA by >50% in only 26%
of patients with AA-resistant disease, compared to 45% of
AA-naı¨ve patients, while all cases in which PSA did not
respond on AA were also resistant to docetaxel [27]. On the
other hand, it was recently reported that cabazitaxel,
another newer taxane, provides significant efficacy in
terms of PSA response and overall survival in patients whose
tumor developed resistance to docetaxel and AA, suggest-
ing that the activity of cabazitaxel is not mainly mediated
by inhibition of AR signaling [18]. These critical clinical
conclusions suggest that mechanisms related to the devel-
opment of resistance to AA are complicated, clearly related
to AR signaling in a subset of patients but also associated
with AR-independent pathways.2.2. Novel anti-AR agents: enzalutamide and ARN-
509
Based on the above presented findings, AR remains active in
CRPC [28], suggesting that AR signaling is a reasonable
target for novel therapies in patients with this state of PCa.
Enzalutamide is a novel antagonist of AR that inhibits its
nuclear translocation and chromatin binding and decreases
the interactions between AR and its co-regulators [29].
Phase I/II studies showed that enzalutamide had significant
activity in men with CRPC [9], which led to the assessment
of this agent in phase III trials showing prolongation of the
survival of patients with chemotherapy-resistant disease by
4.8 months [30]. However, median treatment duration was
short (8.3 months). This agent was also evaluated in
chemotherapy-naı¨ve patients with mCRPC in the phase III
PREVAIL trial [31]. After a median follow-up duration of 22
months, overall survival of a total of 1717 patients was
significantly longer (by 2.2 months) with enzalutamide than
with placebo; risk of radiographic progression was signifi-
cantly lower with enzalutamide than with placebo, and
there was a statistically significant benefit from enzaluta-
mide for all the secondary endpoints, including time to
initiation of chemotherapy and time to PSA progression.
Interestingly, Schrader et al. [32] presented a study in
which patients with docetaxel- and abiraterone-resistant
CRPC were treated with enzalutamide; in three of the
nine patients, the disease did not progress [32]. This finding
suggests that resistance to AA can be partially inhibited by
administration of a novel AR inhibitor such as enzaluta-
mide. For example, AR gain-of-function mutants that can
be activated by non-androgenic steroids that do not requireCYP17A1 for synthesis may contribute to the development
of resistance to AA, but enzalutamide can inhibit AR mu-
tants such as the progesterone-sensitive AR mutant T877A
[16,29].
ARN-509 is a next-generation AR antagonist found to
inhibit AR nuclear translocation and DNA binding, down-
regulate AR transcriptional activity and provide greater
efficacy than any other AR antagonist to which it was
compared [33]. In a recent phase I clinical trial, ARN-509
was notably safe and well-tolerated by patients while of-
fering significant antitumor efficacy; PET imaging demon-
strated robust AR blockade after 4 weeks of treatment [13].
The results of a phase II clinical trial evaluating ARN-509
efficacy in 100 men with CRPC are pending.
The efficacy of two other novel AR antagonists, ODM-201
and ezn-4176, has also been evaluated in clinical trials.
ODM-201 inhibits AR nuclear translocation without agonistic
activity in the context of AR overexpression (Data reported
in 2012 ESMO Congress, Abstract No.: LBA25_PR). The re-
sults of the first multicentered phase I/II dose-escalation
trial in progressive mCRPC (NCT013117641) were recently
presented. A PSA decline of 50% was obtained in 13 of 15
patients (87%) at 12 weeks, including the ones previously
treated with docetaxel (Data reported in 2012 ESMO
Congress, Abstract No.: LBA25_PR). Ezn-4176 is a nucleic
acid-based antisense oligonucleotide targeting AR mRNA.
When administered as a single agent, it specifically inhibi-
ted AR mRNA and decreased AR protein levels, inhibiting
growth of androgen-sensitive and CRPC tumors in vitro and
in vivo [34]. This agent is currently being examined in a
phase I clinical trial (NCT01337518) [35].
Other anti-androgens are in preclinical development.
Compound-30 is a novel anti-androgen developed by opti-
mizing AR ligand-binding efficacy. Guo et al. [36] have
shown that compound-30 inhibited AR activity more
potently than bicalutamide and had a significant antitumor
effect in an in vivo CRPC model. Exploring the capabilities
of this new drug, Kuruma et al. [37] suggested that
compound-30 is a viable therapeutic approach for patients
with CRPC that develop resistance to enzalutamide and
other AR inhibitors. The authors concluded that the new
drug is more potent than enzalutamide in inhibiting AR
transcriptional activity and PCa cell proliferation,
decreasing cell growth and AR transcriptional activity even
in enzalutamide-resistant cells [37].
Finally, a novel approach to the development of AR an-
tagonists is to target the amino-terminus domain of the AR.
The small molecule AR antagonist EPI-001 inhibits pro-
teineprotein interactions necessary for AR transcriptional
activity [38]. This type of anti-AR activity may have distinct
advantages compared to androgen synthesis inhibitors or AR
antagonists that target ligand-AR interactions, since it does
not require interference with ligand-mediated AR activa-
tion. In addition, in preclinical studies EPI-001-based ana-
logs were shown to inhibit constitutively active AR splice
variants that contribute to CRPC and resistance to AR in-
hibitors [39].
Despite this progress, clinical data indicate that mCRPC
tumors only partially respond to novel inhibitors of androgen
synthesis, including AA and AR inhibitors such as enzaluta-
mide, while the disease eventually relapses. Evaluation of
the molecular mechanisms of resistance to these agents is a
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these results and is currently a field of intense research.
3. Mechanisms of resistance to novel anti-AR
signaling agents
3.1. Alterations of AR as mechanisms of resistance
to AR inhibitors
Various studies have reported numerous molecular mecha-
nisms related to AR signaling implicated in the development
of resistance and cancer progression upon androgen
depletion. In particular, increased expression of AR [19],
induction of alternative splicing of AR creating AR splice
variants that lack the ligand-binding domain (LBD) and
remain active under low androgen levels [40], selection for
AR-mutated forms that are sensitive to low levels of an-
drogens [41], and post-transcriptional modifications of AR
that result in its activation even in the absence of andro-
gens have been found to contribute to the development of
CRPC. Although the mechanism of action for AA is different
from that of standard luteinizing hormone releasing hor-
mone agonist-based ADT, and the effects of AA are largely
manifested in the tumor microenvironment, we could hy-
pothesize that similar mechanisms may underlie resistance
to standard ADT and AA, on the basis of a common down-
stream therapeutic action, i.e., androgen depletion.
AR mutations have been found to occur more frequently
in CRPC than in hormone-naı¨ve tumors [42]; in fact, recent
data show that AR is one of the most frequently mutated
genes in mCRPC [43]. Earlier studies have highlighted the
role of AR mutations, including the T877A mutant, which
increases the sensitivity of AR to steroids [44] and converts
anti-androgens to strong agonists [45], in the development
of resistance to AR antagonists such as flutamide [46]. Ac-
cording to a recent report by Korpal et al. [47], LNCaP
clones resistant to enzalutamide do not present significant
differences in terms of AR expression and nuclear trans-
location compared to baseline cell lines. However,
sequencing analysis revealed that all of the strongly resis-
tant clones express the F876L mutation in AR, which
switches the inhibitory effects of enzalutamide to agonistic
activity [47]. Similarly, clones resistant to ARN-509 express
the F867L mutation, while circulating cancer cells from
cases in which resistance to ARN-509 developed expressed
this particular mutation at a higher frequency than cases in
which this resistance did not develop [48]. These findings
suggest that treatment with AR inhibitors targeting the
LBD, such as enzalutamide and ARN-509, may select for
mutations that alter the sensitivity of AR to steroids and
convert the antagonistic effects of these agents to
agonistic. Interestingly, Noonan et al. [49] and Loriot et al.
[50] demonstrated that PCa patients that progress on
enzalutamide therapy may respond to AA, further sug-
gesting that there are distinct mechanisms of resistance to
these two agents.
AR amplification has been reported in relapsed PCa
following androgen depletion, but its incidence is not
considered high enough to fully explain the development of
CRPC [8,51,52]. Interestingly, it has been reported that
increased expression of AR related to its amplificationconverts the anti-androgenic effects of an old AR inhibitor,
bicalutamide, to induced activity [53]. On the other hand,
AR amplification was detected in a man with mCRPC whose
disease subsequently responded to enzalutamide, with loss
of AR amplification and gain of MYC and c-MET amplification
noted at progression (Data reported on 2014 Genitourinary
Cancers Symposium, Abstract No.: 65). This finding suggests
that the mechanisms of resistance to novel anti-androgens
are not limited to AR-related signaling but may also be
associated with derepression of alternative oncogenic
signaling (discussed later in this review).3.2. Expression of AR splice variants as a
mechanism of resistance to anti-AR signaling agents
Alternative splicing of AR leads to formation of AR species
lacking the LBD that are constitutively active despite
androgen depletion and is believed to be implicated in the
development of resistance to hormonal therapy [54]. Thus,
the formation of AR variants as a mechanism of resistance
to novel anti-androgen agents is now a subject of intense
research.
Mostaghel et al. [17] demonstrated that AA is associated
with rapid formation of C-terminaletruncated constitu-
tively active AR-Vs lacking the LBD, leading to development
of resistance. Interestingly, according to a recent study by
Antonarakis et al. [55] that evaluated mRNA levels of AR-V7
in circulating cancer cells from patients receiving AA, none
of the AR-V7-positive patients achieved PSA response
50%, whereas 68% of the AR-V7-negative patients did.
Thus, AR-V7-positive patients were more than 16 times
more likely to experience both PSA and clinical progression
concluding that expression of AR-V7, one of the most
frequently detected AR splice variants, is associated with
poor response to AA in patients with mCRPC. This finding
suggests that common mechanisms may underlie the
development of CRPC and resistance to AA. On the other
hand, another recent study by Small et al. showed that
mCRPC resistant to AA expresses lower levels of AR than AA-
naı¨ve mCRPC, suggesting that AA selects for tumors with
lower levels of AR, representing disease less dependent on
AR (Data reported at also 2014 ASCO Annual Meeting,
Abstract No.: 5020). Antonarakis et al. [55] also reported
that expression of AR-V7 predicts for poor response to
enzalutamide, suggesting that AR variant formation may be
a common mechanism of resistance to novel anti-androgen
agents. Specifically, they found that patients who had
AR-V7 in their circulating tumor cells had worse response to
enzalutamide than those without detectable AR-V7 in a
total sample of 31 patients. PSA levels did not decline in
any of the patients with detectable AR-V7; in fact, no pa-
tient with detectable AR-V7 achieved a PSA response, while
PSA levels dropped by at least 50% in 10 of the 19 AR-V7-
negative patients after enzalutamide treatment [55].
Consistent with these clinical data was the finding that the
expression of AR variants driven by AR gene rearrangements
is sufficient for resistance to enzalutamide in CWR22Rv1
cells, inducing a transcriptional program that is similar to
that of the full-length AR [15]. Hu et al. [56] demonstrated
that enzalutamide treatment promotes expression of the
AR-V7 variant similarly to AR siRNA treatment, further
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ment of resistance to enzalutamide. Moreover, Nadiminty
et al. [57] found that upregulation of AR variants by NF-
kB2/p52 induces resistance to enzalutamide in LNCaP C4-2B
and CWR22Rv1 PCa cells, while knockdown of either full-
length AR or the AR-V7 variant increased the efficacy of
enzalutamide in these two cell lines. Given the evidence
presented here that resistance to enzalutamide and
ARN-509 is associated with alterations or deletions through
alternative splicing of the LBD, small molecules such as
EPI-001 that target the N-terminal AR domain [39] are
considered to be promising novel therapeutic candidates
for patients with CRPC.
The development of AA to decrease androgen biosyn-
thesis in the tumor microenvironment and enzalutamide,
ARN-509 and other novel anti-androgens to inhibit AR
signaling, as single agents or in combination, represent
novel approaches to maximal AR signaling inhibition. With
regard to combination approaches, a phase III trial is un-
derway to test the concept that two separate anti-AR
signaling agents, i.e., AA and enzalutamide that act at
different levels, will be more effective than single-agent
inhibitors that act at one level (NCT01949337). Given that
numerous studies have highlighted the role of alternativeFigure 1 Resistance mechanisms associated with novel agents
(abiraterone acetate) or inhibiting AR (enzalutamide and ARN-509)
amplifications, mutations, and AR variants, are implicated in the d
nation of abiraterone acetate and an AR inhibitor leads to maxima
derepression of alternative oncogenic signaling at the transcription
These signaling activities set the stage for the introduction of nove
signaling pathways. Specifically, induction of the expression of c-M
such as cabozatinib and DZNep, respectively, while the induction o
and development of a stem cell phenotype has resulted in testing
inhibitors, and IL-6 inhibitors, respectively. The final therapeutic g
anti-AR signaling agents) and alternative signaling (novel agents
neuroendocrine; GR, glucocorticoid receptor.oncogenic signaling such as c-myc and Akt in the develop-
ment of PCa [58,59], it can be hypothesized that the ma-
jority of patients whose disease progresses under maximal
AR inhibition will have a cancer less dependent on AR and
more dependent on these alternative oncogenic signaling
pathways (Fig. 1).4. Alternative signaling and resistance to
maximal androgen depletion
The maximal AR inhibition that probably can be achieved by
combining androgen depletion in the tumor microenviron-
ment (AA) and AR inhibition by novel agents (enzalutamide
or ARN-509) is expected to select for cancer cells with
minimal or no dependency on AR signaling. Maximal AR in-
hibition can be a strong selective pressure for induction
and/or manifestation of alternative pathways promoting
survival and growth of PCa cells independently of AR [60].
This would partly explain the clinical observation that a
subset of patients experience very rapid progression upon
systemic androgen depletion or AR inhibition by novel anti-
androgen agents. It can be hypothesized that alternative
oncogenic signaling may be already activated in thesethat target AR signaling by decreasing androgen biosynthesis
. Induced androgen biosynthesis and alterations of AR, such as
evelopment of resistance to these novel agents, while combi-
l AR inhibition. This downregulation of AR signaling can lead to
al level and through induction of various oncogenic pathways.
l therapeutic approaches targeting these alternative oncogenic
et and EZH2 has led to the experimental trial of novel agents
f oncogenic signaling pathways including PI3K/Akt, autophagy
novel agents such as BEZ235, early and late stage autophagy
oal is combination pharmaceutical targeting of both AR (novel
) early during PCa progression. AR, androgen receptor; NE,
Novel anti-androgen receptor signaling agents 35tumors prior to initiation of the hormonal or novel anti-
androgen therapy, which would further induce these
pathways through the mechanism of selection. The neces-
sity for predictive biomarkers for these novel anti-AR
agents is evident from these initial clinical studies.
According to this general concept, AR may repress
oncogenic signaling in PCa cells and AR inhibition may
derepress these pathways, rendering the PCa progression
more dependent on them. Given that the majority of pa-
tients with CRPC are now treated with novel anti-androgen
agents such as enzalutamide and AA, it is really critical to
consider the hypothesis that maximal AR inhibition by these
agents may lead to derepression of alternative oncogenic
signaling in CRPC, promoting survival and growth of cancer
cells. Based on this idea, numerous studies have revealed
that enzalutamide can induce several pathways with
oncogenic potential in PCa cells.
To explore and develop new insight into the concept of
derepression of oncogenic pathways by novel anti-AR
signaling agents, we will describe particular examples of
this phenomenon, focusing on (1) specific examples of gene
derepression at the transcriptional level and (2) promotion
of oncogenic signaling by anti-AR-signaling.4.1. AR inhibition-mediated derepression of
oncogene transcription
The concept that androgen deprivation and subsequent AR
inhibition may derepress particular AR-suppressed genes
was supported by the recent findings of Cai et al. [61]. The
authors showed that androgen-liganded AR decreases the
expression of AR gene by repressing the activity of ARBS2 as
a transcriptional enhancer [61]. Moreover, the authors
demonstrated that numerous genes related to DNA syn-
thesis and repair, DNA metabolism and cell cycle are also
repressed by androgen-liganded AR and are induced under
androgen depletion, while genes related to cellular meta-
bolism were found to be induced by androgen-liganded AR.
Interestingly, many of these androgen-liganded AR-
repressed genes were shown to be upregulated in CRPC
VCaP xenografts together with some androgen-liganded AR-
induced genes implicated in cellular metabolism. According
to the authors, the intratumoral synthesis of androgens in
the state of CRPC leads to partial restoration of AR tran-
scriptional activity, while these levels are not sufficient to
downregulate the expression of androgen-liganded AR-
repressed genes related to cell cycle and DNA metabolism
[61]. Thus, the results of this study highlight that inhibition
of androgen biosynthesis combined with AR inhibition
through combinational approaches may lead to derepres-
sion of alternative oncogenic signaling, favoring the survival
of PCa cells and disease progression.
c-Met is another example of AR inhibition-mediated
derepression of an oncogene. This molecule, which func-
tions as an hepatocyte growth factor receptor in PCa cells,
promoting PCa proliferation and invasion [62], was found to
be induced by castration in LNCaP cells [63]. Particularly, it
was demonstrated that AR represses c-Met expression
through binding in its promoter [63], providing a clear
rationale behind the derepression phenomenon. Notably,
c-Met is targetable through novel inhibitors such ascabozantinib, which is currently being evaluated in two
phase III clinical trials in comparison with prednisone and
mitoxantrone (COMET-1 [NCT01605227] and COMET-2
[NCT01522443]). Thus, it would be important to examine
the efficacy of the combination of cabozantinib with
enzalutamide and abiraterone in this disease setting.
Indeed, a phase II randomized clinical trial evaluating the
combination of cabozantinib and abiraterone in chemo-
therapy-naı¨ve mCRPC is currently ongoing (NCT01995058).
Recently, enzalutamide was found to increase the
expression of c-Myb [64], a transcriptional factor reported
to be induced in aggressive breast, head and neck and
prostate cancers [65]. It was demonstrated that c-Myb in-
creases growth and metastatic potential of both AR-
positive and -negative PCa cells [64]. AR and c-Myb were
also found to share a signature of DNA damage response
(DDR)-related genes strongly associated with cancer
recurrence, castration resistance, and metastatic disease
[64]. These results point to a c-Myb-mediated mechanism of
resistance to enzalutamide related to DDR. This pathway
was correlated with resistance to the novel PARP inhibitor
olaparib, showing that inhibition of this pathway combined
with olaparib can significantly increase PCa cell toxicity. On
the basis of these findings, we can hypothesize that tar-
geting c-Myb in combination with enzalutamide or maximal
AR inhibition could be particularly effective in patients with
CRPC. The finding of Li et al. [64] that c-Myb regulates DDR
through Topbp1, the ataxia-telangiectasia and Rad3-
related protein (ATR) and Chk1 protein, which regulate DDR
checkpoints, supports that combination of enzalutamide
with inhibitors of these c-Myb downstream targets may be
effective in PCa.
According to a recent study, activated AR leads to
downregulation of enhancer of zeste homolog 2 (EZH2)
[66]. EZH2, which is induced in various malignancies such as
PCa, functions as an epigenetic gene silencer of genes such
as E-cadherin, which inhibits epithelial cell migration [67].
Notably, it has been shown that treatment with androgens
decreases the migration of LNCaP cells, but downregulation
of E-cadherin abrogated this effect [66]. Finally, Xu et al.
[68] demonstrated that castration-resistant LNCaP abl cells
are more sensitive to EZH2 downregulation than castration-
sensitive LNCaP cells, further highlighting the critical role
of EZH2 in the development of CRPC. Interestingly, 3-
deazaneplanocin A (DZNep), a potent S-adenosylhomocys-
teine hydrolase inhibitor, was found to effectively deplete
potentially oncogenic PRC2 components EZH2, SUZ12 and
H3K27me3, resulting in reactivation of EZH2-repressed
target genes [69]. Further studies are needed to clarify
the effect of enzalutamide and other novel anti-androgen
agents on EZH2 expression and downstream signaling in
PCa. Finally, combinations of novel anti-androgen agents
with EZH2-targeting agents such as DZNep may have ben-
efits for patients with aggressive metastatic PCa.
According to a report by Sahu et al. [70], AR and
glucocorticoid receptor (GR) have overlapping sets of gene
targets, supporting that induction of GR can be a potential
mechanism related to development of CRPC. It was
recently demonstrated that GR and common target genes
of AR and GR are upregulated in LNCaP xenografts resistant
to enzalutamide [71]. The authors also found that GR in-
hibition in resistant cells can potentiate their sensitivity to
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in tumors that had a poor response to enzalutamide at 8
weeks of treatment compared to baseline and to those that
had a good response at the same time point [71]. These
results suggested that AR directly represses GR expression
at the transcriptional level [71]. It could be hypothesized
that, in a subset of prostate tumors, AR can repress GR
expression while enzalutamide treatment leads to induc-
tion of GR, which becomes critical for the survival of cancer
cells. These results also support the suggestion that com-
bination of maximal AR inhibition with GR inhibition may be
a reasonable therapeutic approach for CRPC and improve
the survival and quality of life of patients with this disease.
Finally, the discovery of reliable markers downstream of GR
for the identification of patients with induced GR pathway
is critical for the development of this approach.4.2. Promotion of oncogenic signaling by AR
inhibition
Numerous recent studies have focused more on the dere-
pression of oncogenic signaling by novel anti-AR signaling
agents, mainly enzalutamide, at the post-transcriptional
level, such as protein interactions and phosphorylation. In
particular, Carver et al. [72] found that enzalutamide
treatment increased the phosphorylation of Akt in PTEN-
deleted LNCaP cells and LAPC4 cells, while the combina-
tion of enzalutamide and BEZ235, a PI3K inhibitor, caused
marked regression of PCa in animal models. These effects
of enzalutamide were attributed to induction of the Akt
phosphatase PHLPP by AR inhibition and are consistent with
the findings of another study, by Mulholand et al. [73], who
demonstrated that AR inhibition, either by castration or AR
loss, released PHLPP-mediated suppression of Akt activity
and induced Akt-dependent but AR-independent PCa cell
proliferation.
It was recently discovered that enzalutamide induces
autophagy in both androgen-responsive and CRPC cells,
mainly through AMP-dependent protein kinase (AMPK)
activation [74]. Autophagy is an intracellular degradation
system that delivers cytoplasmic constituents to the lyso-
somes to regenerate energy when the cells are confronted
with stressful conditions such as growth factor deprivation
or toxic drugs [74,75]. It is known that exaggerated auto-
phagy can result in autophagic cell death, also known as
type II programmed cell death, and thus has a role in tumor
suppression, whereas more generalized deregulation has
been linked to non-apoptotic cell death. On the other hand,
autophagy was shown to promote resistance to chemo-
therapy in numerous malignancies [76]. Recently this
intracellular pathway was reported to be a survival mech-
anism mediating resistance to AR inhibitors in CRPC cells
[77]. Consistent with these results was the observation by
Nguyen et al. [74] that AR inhibition by enzalutamide
caused significant induction of autophagy through activa-
tion of the AMPK pathway and suppression of mTOR down-
stream signaling via phosphorylation of Raptor. According
to their preclinical data, when resistance to enzalutamide
develops, pharmacological blocking of autophagy bypasses
the resistance and achieves better therapeutic results.
These results could also be an example of the benefitgained by combination therapy that includes a novel anti-
androgen and inhibition of a survival pathway. However,
these results point to the need for further studies to clarify
whether the mechanistic complexity of autophagy can be
exploited in CRPC.
The development of resistance to enzalutamide is
associated with the stem-cell phenotype in PCa [78,79]. In
particular, Bishop et al. [79] having studied patients un-
dergoing long-term androgen withdrawal therapy, indi-
cated that all cancer stem cell markers were expressed at a
higher frequency in enzalutamide-resistant cells than in
CRPC controls, while neuroendocrine markers were also
highly upregulated in these cells. In addition, the majority
of the neuroendocrine-like enzalutamide resistant cells
expressed PD-L1 and PD-L2 that are known to downregulate
T cell-effector responses and engage signaling molecules
that have been evaluated as immunotherapy targets. Thus,
the emergence of neuroendocrine-like cells through the
development of resistance to enzalutamide may be asso-
ciated with suppression of antitumor T cell responses
leading to increased aggressiveness of the disease. At the
same time, these data suggest that immunotherapy ap-
proaches such as targeting PD-L: PD-1 pathway in combi-
nation with enzalutamide may be a reasonable approach
for this subset of patients. Finally, Schroeder et al. [78]
showed that inhibition of the IL-6-STAT3 pathway reduces
the prostate stem-like cancer cell population and prostate
tumor growth supporting the approach of combining in-
hibitors of IL-6 and novel anti-androgen agents.
Svensson et al. [80] using chromatin immunoprecipita-
tion data and location analysis by confocal microscopy and
proximity ligation assays, found that AR and the repressor
element-1 silencing transcription factor (REST) coexist in
close proximity in PCa cells, suggesting functional crosstalk
between them. The authors demonstrated that androgen
deprivation, AR knockdown, or enzalutamide led to
decreased REST protein levels and induction of genes
associated with neuroendocrine differentiation, such as
chromogranin A [80]. The expression of REST was evaluated
in tissue microarray sections from prostatectomies and this
analysis showed that REST was strongly associated with AR
expression while low REST nuclear abundance in these
specimens strongly predicted disease recurrence within 3
years after surgery [80]. These data suggest that AR
signaling regulates the expression of the transcriptional
silencer REST, while ADT and enzalutamide can down-
regulate this factor, leading to upregulation of genes
implicated in neuroendocrine differentiation of PCa cells.
Thus, treatment with enzalutamide may induce neuroen-
docrine differentiation in CRPC, which has been associated
with rapid disease progression and poor prognosis [81].
The data presented here suggest that AR inhibition with
enzalutamide promotes the derepression of numerous
oncogenic pathways, potentially through survival selection,
setting the stage for development of AR-independent
aggressive PCa. Two critical points arise from this conclu-
sion: (1) although an attractive therapeutic approach for
CRPC, the combination of AA and enzalutamide for
achieving maximal AR inhibition will require identification
of those patients whose tumors will respond to this treat-
ment by induction of specific oncogenic pathways and will
rapidly develop resistance. The understanding of these
Novel anti-androgen receptor signaling agents 37biological processes is critical for the development of novel
predictive biomarkers, which may improve the progression-
free survival and overall survival benefits of these agents;
(2) the combination of maximal AR inhibition with inhibition
of alternative derepressed oncogenic signaling is a reason-
able therapeutic approach for CRPC patients given the
findings from numerous recent preclinical studies. Predic-
tive biomarkers are critical to get the maximum benefit
from novel therapies targeting these pathways.
A clinical trial presented as an abstract at the 2014
Annual Meeting of the American Society for Clinical
Oncology evaluated the combination of systemic androgen
deprivation with docetaxel in patients with hormone-naı¨ve
metastatic PCa. The investigators showed that the addition
of docetaxel to hormonal therapy significantly prolonged
overall survival (57.6 vs. 44.0 months) and that the survival
benefit was more impressive for patients with high-extent
disease (49.2 vs. 32.2 months). Moreover, a greater pro-
portion of patients assigned to docetaxel demonstrated a
PSA 2 ng/mL after 1 year (22.7% vs. 11.7%) and delayed
median time to clinical progression (32.7 vs. 19.8 months).
These impressive results support the idea that combina-
tional approaches may be very effective when they are
used early during disease progression. This concept may
lead to a paradigm shift for patients with mCRPC who are
receiving a novel anti-androgen agent such as AA or enza-
lutamide, as the data suggest that introduction of a novel
agent in combination with AR inhibition early during disease
progression can provide significant advantages for patients
with aggressive PCa.
5. Conclusion
Recent results from clinical trials presented in this review
indicate that novel anti-androgen agents, such as AA and
enzalutamide, provide certain/limited progression-free
survival and overall survival benefits in patients with CRPC.
Numerous mechanisms are implicated in the development of
resistance to these agents. AR alteration and the derepres-
sion of alternative oncogenic signaling by AR inhibition seem
to make an important contribution to progression of the
disease during treatment with these novel agents. Clinical
data suggest that the combination of these two agents leads
tomaximal AR inhibition, and this approach is currently being
evaluated in the treatment of CRPC. However, preclinical
studies presented in this review indicate that AR inhibition by
enzalutamide leads to promotion of oncogenic pathways
such as GR, c-Myb, autophagy and development of a stem
cell-phenotype in PCa cells. These findings suggest that PCa
cells with activated alternative signaling will become rapidly
resistant to AR inhibition, whereas their survival will become
more dependent on these pathways, rendering early treat-
mentwith a combination ofmaximal AR inhibition and agents
that target these pathways a promising novel approach for
patients with CRPC. Further preclinical studies and clinical
trials evaluating the efficacy of these combination treat-
ments are needed.
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